Immunocore Holdings Stock Performance
| IMCR Stock | USD 32.74 0.09 0.27% |
The company retains a Market Volatility (i.e., Beta) of 1.06, which attests to a somewhat significant risk relative to the market. Immunocore Holdings returns are very sensitive to returns on the market. As the market goes up or down, Immunocore Holdings is expected to follow. At this point, Immunocore Holdings has a negative expected return of -0.12%. Please make sure to check out Immunocore Holdings' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Immunocore Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immunocore Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest weak performance, the Stock's fundamental indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (0.27) | Five Day Return 0.43 | Year To Date Return (54.30) | Ten Year Return (24.21) | All Time Return (24.21) |
1 | Disposition of 8676 shares by Herbst Roy Steven of Immunocore Holdings at 58.69 subject to Rule 16b-3 | 09/17/2024 |
2 | Immunocore Holdings plc Hits 52-Week Low Despite 34 percent Surge in KIMMTRAK Sales | 09/25/2024 |
3 | Is Immunocore Holdings Using Debt Sensibly | 10/24/2024 |
4 | Discretionary transaction by Baker Bros. Advisors Lp of 674261 shares of Immunocore Holdings subject to Rule 16b-3 | 10/25/2024 |
5 | Immunocore Shares Up 7.4 percent Whats Next | 10/30/2024 |
6 | Immunocore Holdings PLC Q3 2024 Earnings EPS of 0.17 Beats Estimates, Revenue at 80.2 Million | 11/06/2024 |
7 | Wall Street Analysts Predict an 112.56 percent Upside in Immunocore Heres What You Should Know | 11/08/2024 |
8 | Immunocores SWOT analysis biotech stock faces pivotal moment amid PRAME data | 11/12/2024 |
9 | AbbVies Ovarian Cancer Drug Elahere Gets Approval in Europe | 11/18/2024 |
10 | ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap | 11/19/2024 |
11 | FDA Accepts GSKs BLA for Blenrep Combos in Multiple Myeloma | 11/26/2024 |
| Begin Period Cash Flow | 402.5 M |
Immunocore |
Immunocore Holdings Relative Risk vs. Return Landscape
If you would invest 3,608 in Immunocore Holdings on September 2, 2024 and sell it today you would lose (334.00) from holding Immunocore Holdings or give up 9.26% of portfolio value over 90 days. Immunocore Holdings is currently does not generate positive expected returns and assumes 2.4189% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Immunocore, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunocore Holdings Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunocore Holdings' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunocore Holdings, and traders can use it to determine the average amount a Immunocore Holdings' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0507
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMCR |
Estimated Market Risk
| 2.42 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immunocore Holdings is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunocore Holdings by adding Immunocore Holdings to a well-diversified portfolio.
Immunocore Holdings Fundamentals Growth
Immunocore Stock prices reflect investors' perceptions of the future prospects and financial health of Immunocore Holdings, and Immunocore Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunocore Stock performance.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0522 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 1.22 B | ||||
| Shares Outstanding | 50.03 M | ||||
| Price To Book | 4.34 X | ||||
| Price To Sales | 5.54 X | ||||
| Revenue | 249.43 M | ||||
| Gross Profit | 54.11 M | ||||
| EBITDA | (51.65 M) | ||||
| Net Income | (43.37 M) | ||||
| Cash And Equivalents | 208.06 M | ||||
| Cash Per Share | 4.74 X | ||||
| Total Debt | 84.03 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 3.98 X | ||||
| Book Value Per Share | 7.55 X | ||||
| Cash Flow From Operations | 2.94 M | ||||
| Earnings Per Share | (0.95) X | ||||
| Market Capitalization | 1.64 B | ||||
| Total Asset | 597 M | ||||
| Retained Earnings | (744.67 M) | ||||
| Working Capital | 389.8 M | ||||
About Immunocore Holdings Performance
Assessing Immunocore Holdings' fundamental ratios provides investors with valuable insights into Immunocore Holdings' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Immunocore Holdings is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.6 K | 1.7 K | |
| Return On Tangible Assets | (0.09) | (0.10) | |
| Return On Capital Employed | (0.13) | (0.14) | |
| Return On Assets | (0.09) | (0.10) | |
| Return On Equity | (0.15) | (0.16) |
Things to note about Immunocore Holdings performance evaluation
Checking the ongoing alerts about Immunocore Holdings for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunocore Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunocore Holdings generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 249.43 M. Net Loss for the year was (43.37 M) with profit before overhead, payroll, taxes, and interest of 54.11 M. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: FDA Accepts GSKs BLA for Blenrep Combos in Multiple Myeloma |
- Analyzing Immunocore Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunocore Holdings' stock is overvalued or undervalued compared to its peers.
- Examining Immunocore Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunocore Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunocore Holdings' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunocore Holdings' stock. These opinions can provide insight into Immunocore Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.